Nipogalin (Cefuroxime)

Cefuroxime, the active ingredient in Nipogalin, is a second‑generation cephalosporin presented as an oral tablet for oral use. It treats bacterial infections of the respiratory tract, urinary system, skin and soft tissues, and sinus cavities in adult and pediatric patients when prescribed by a healthcare professional.

GNH USA supplies Nipogalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics and dedicated customer support.

Cefuroxime is a second‑generation cephalosporin antibiotic used to treat bacterial infections affecting several organ systems.

Respiratory tract infections: eliminates susceptible bacteria, helping to resolve pneumonia, bronchitis and related symptoms. Urinary tract infections: targets common uropathogens, facilitating clearance of cystitis and pyelonephritis. Skin and soft‑tissue infections: combats Staphylococcus and Streptococcus species, aiding healing of cellulitis, abscesses and wound infections. Sinusitis: reduces bacterial load in the sinus cavities, supporting symptom relief and recovery.

Cefuroxime may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset often occurring shortly after dosing. - Diarrhea: loose stools that may be watery and transient. - Headache: mild tension‑type headache reported by some patients. - Rash: mild skin erythema or pruritus without systemic involvement. - Vomiting: occasional episodes of nausea and expulsion of stomach contents.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction with hives, swelling and respiratory distress. - Stevens‑Johnson syndrome: rare skin disorder with blistering and mucosal involvement. - Clostridioides difficile‑associated colitis: severe diarrhea due to overgrowth of C. difficile. - Hemolytic anemia: destruction of red blood cells leading to fatigue and pallor.

When prescribing cefuroxime, clinicians should consider several precautionary measures to ensure safe and effective therapy. - Renal function assessment: adjust dose in patients with impaired kidney clearance. - Beta‑lactam allergy history: avoid use in individuals with known hypersensitivity to penicillins or cephalosporins. - Superinfection risk: monitor for secondary infections such as fungal overgrowth during prolonged therapy. - Elderly patients: start with lower doses and observe for adverse reactions due to altered pharmacokinetics. - Concomitant anticoagulants: watch for enhanced bleeding risk when combined with warfarin. - Store at room temperature: keep in the original container, protect from moisture and light.

Cefuroxime can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Probenecid: reduces renal excretion of cefuroxime, leading to higher plasma concentrations. - Warfarin: potentiates anticoagulant effect, increasing risk of bleeding. - Antacids containing aluminum or magnesium: decrease cefuroxime absorption, reducing therapeutic levels. - Methotrexate: increased serum levels may cause toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in efficacy, advise additional contraceptive measures. - Diuretics: may enhance potassium loss, monitor electrolyte balance. - NSAIDs: combined use can affect renal function, especially in at‑risk patients. - Ciprofloxacin: may increase risk of tendon rupture when combined. - Statins: monitor for myopathy risk.